

PCT REQUEST

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM


022-2003 WO1

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Danish Patent and Trademark Office (RO/DK)
0-7	Applicant's or agent's file reference	022-2003 WO1
I	Title of invention	METHOD FOR TREATING DIABETES AND RELATED DISORDERS
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	ZEALAND PHARMA A/S
II-5	Address:	Smedeland 26B DK-2600 Glostrup Denmark
II-6	State of nationality	DK
II-7	State of residence	DK
II-8	Telephone No.	+45 43 28 12 00
II-9	Facsimile No.	+45 43 28 12 12
II-10	e-mail	lsd@zp.dk
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	STEINESS, Eva
III-1-5	Address:	Sømarksvej 11 DK-2900 Hellerup Denmark
III-1-6	State of nationality	DK
III-1-7	State of residence	DK

BEST AVAILABLE COPY

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW</p>
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI-1	Priority claim of earlier national application	
VI-1-1	Filing date	04 July 2002 (04.07.2002)
VI-1-2	Number	60/393,917
VI-1-3	Country	US

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

VI-2	Priority claim of earlier national application			
VI-2-1	Filing date	24 April 2003 (24.04.2003)		
VI-2-2	Number	60/465,613		
VI-2-3	Country	US		
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)		
VIII	Declarations	Number of declarations		
VIII-1	Declaration as to the identity of the inventor	-		
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-		
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-		
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-		
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-		
IX	Check list	number of sheets	electronic file(s) attached	
IX-1	Request (including declaration sheets)	4	-	
IX-2	Description	43	-	
IX-3	Claims	10	-	
IX-4	Abstract	1	EZABST00.TXT	
IX-5	Drawings	8	-	
IX-7	TOTAL	66		
	Accompanying items	paper document(s) attached	electronic file(s) attached	
IX-8	Fee calculation sheet	✓	-	
IX-17	PCT-EASY diskette	-	Diskette	
IX-19	Figure of the drawings which should accompany the abstract			
IX-20	Language of filing of the international application	English		
X-1	Signature of applicant, agent or common representative			
X-1-1	Name			ZEALAND PHARMA A/S
X-1-2	Name of signatory			Maj Hilligsø
X-1-3	Capacity	Patent Manager		
X-2	Signature of applicant, agent or common representative			
X-2-1	Name (LAST, First)	STEINESS, Eva		

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
------	---	--

PCT REQUEST

4/4

022-2003 WO1

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

1/2

022-2003 WO1

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only	
0-1	International Application No.	
0-2	Date stamp of the receiving Office	
0-4	Form - PCT/RO/101 (Annex)	
0-4-1	PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-9	Applicant's or agent's file reference	022-2003 WO1
2	Applicant	ZEALAND PHARMA A/S, et al.
12	Calculation of prescribed fees	fee amount/multiplier Total amounts (DKK)
12-1	Transmittal fee T	⇒ 1,500
12-2-1	Search fee S	⇒ 7,030
12-2-2	International search to be carried out by	EP
12-3	International fee	
	Basic fee	
	(first 30 sheets) b1	3,300
12-4	Remaining sheets	36
12-5	Additional amount (X)	80
12-6	Total additional amount b2	2,880
12-7	b1 + b2 = B	6,180
12-8	Designation fees	
	Number of designations contained in international application	97
12-9	Number of designation fees payable (maximum 5)	5
12-10	Amount of designation fee (X)	710
12-11	Total designation fees D	3,550
12-12	PCT-EASY fee reduction R	-1,020
12-13	Total International fee (B+D-R) I	⇒ 8,710
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒ 17,240
12-19	Mode of payment	cheque

VALIDATION LOG AND REMARKS

13-2-7	Validation messages Contents	Green? Figure of the drawings which should accompany the abstract not specified. Please verify.
		Green? Priority 1. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)

PCT (ANNEX - FEE CALCULATION SHEET)

2/2

022-2003 WO1

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

		Green? Priority 2. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
13-2-8	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available

Abstract

The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a "drug holiday". Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.

Original (for **SUBMISSION**) - printed on 02.07.2003 11:20:44 AM**PCT-EASY INFORMATION SHEET**

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

Green?	Contents
Green?	Figure of the drawings which should accompany the abstract not specified. Please verify.
Green?	Priority 1. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
Green?	Priority 2. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
	Fees
Green?	Please confirm that fee schedule utilized is the latest available

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box X of the Request form has been signed;
- all elements of the international application as indicated in Boxes VIII and IX of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The electronic version of the PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must reopen the stored form for submission, perform necessary amendments and immediately resubmit the form. Finally, a NEW submission diskette must be created manually by resending the corrected stored form to the diskette. The previously created printout and submission diskette must be destroyed in order to prevent the possibility of erroneously sending it to the RO.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.